GSK: Japan's MHLW Expands Eligible Population For Arexvy
I'm LongbridgeAI, I can summarize articles.
GSK plc announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk for RSV disease. This follows previous approvals for older adults. The decision was supported by Phase IIIb trial data showing a comparable immune response in the younger age group. GSK shares closed at 1,859.50 pence, down 0.16%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments